HC Wainwright Cuts Outlook Therapeutics (NASDAQ:OTLK) Price Target to $3.00

Outlook Therapeutics (NASDAQ:OTLK) had its price objective reduced by HC Wainwright from $30.00 to $3.00 in a report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Outlook Therapeutics’ Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($2.33) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at $0.62 EPS, FY2028 earnings at $2.37 EPS and FY2029 earnings at $3.24 EPS.

Other equities analysts have also issued research reports about the stock. BTIG Research lowered their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, Guggenheim reaffirmed a “buy” rating and set a $12.00 target price on shares of Outlook Therapeutics in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Outlook Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Outlook Therapeutics Stock Down 3.2 %

Shares of NASDAQ OTLK opened at $1.64 on Tuesday. The firm’s 50-day moving average price is $1.89 and its two-hundred day moving average price is $4.33. Outlook Therapeutics has a 52-week low of $0.87 and a 52-week high of $12.85. The stock has a market capitalization of $52.51 million, a P/E ratio of -0.22 and a beta of 0.58.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings results on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04). As a group, equities research analysts expect that Outlook Therapeutics will post -2.25 earnings per share for the current year.

Institutional Investors Weigh In On Outlook Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OTLK. Geode Capital Management LLC increased its position in shares of Outlook Therapeutics by 49.2% during the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after purchasing an additional 112,812 shares during the period. State Street Corp boosted its stake in Outlook Therapeutics by 10.0% during the third quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after buying an additional 21,201 shares in the last quarter. Rhumbline Advisers grew its holdings in Outlook Therapeutics by 1,329.6% during the fourth quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock worth $355,000 after acquiring an additional 174,896 shares during the period. Renaissance Technologies LLC bought a new stake in Outlook Therapeutics in the fourth quarter worth about $246,000. Finally, Scotia Capital Inc. lifted its holdings in Outlook Therapeutics by 124.4% in the 4th quarter. Scotia Capital Inc. now owns 73,989 shares of the company’s stock valued at $140,000 after acquiring an additional 41,023 shares during the last quarter. Institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.